Prolynx Secures $70 Million Series A to Advance Portfolio of Ultra-Long-Acting Obesity Candidates and Appoints Chris Boulton as Chief Executive Officer
Summary
Prolynx has raised $70 million in Series A financing to advance its portfolio of ultra-long-acting obesity and metabolic disease candidates. The company plans to use the capital to push its extended-duration incretin and non-incretin therapies toward IND enablement and clinical proof-of-concept. Prolynx also appointed Chris Boulton as chief executive officer, while founder Daniel Santi moves into the chief technical and scientific officer role. The financing was led by 5AM Ventures, OrbiMed, and Monograph Capital, and the investors have joined the board.
Funding
Amount
$70.0M
Total raised
Date
December 11, 2025
Announcement date
Investors
OrbiMed, 5AM Ventures
Lead investors
Company
https://prolynxinc.com/
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected